Robert Califf may be willing to give advisory committee opinions a little more influence should he become commissioner of the US Food and Drug Administration.
Califf hinted during his 14 December Senate confirmation hearing that an overwhelming advisory committee vote should warrant close scrutiny by agency officials before making a decision.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?